1. Bcl‐2/Bcl‐xL inhibition predominantly synergistically enhances the anti‐neoplastic activity of a low‐dose CUSP9 repurposed drug regime against glioblastoma. (30th July 2019) Authors: Halatsch, Marc‐Eric; Kast, Richard Eric; Dwucet, Annika; Hlavac, Michal; Heiland, Tim; Westhoff, Mike‐Andrew; Debatin, Klaus‐Michael; Wirtz, Christian Rainer; Siegelin, Markus David; Karpel‐Massler, Georg Journal: British journal of pharmacology Issue: Volume 176:Number 18(2019) Page Start: 3681 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CBMT-35. METABOLIC REWIRING BY ONC201/TIC10 AND 2-DEOXYGLUCOSE HAS SYNERGISTIC ANTI-GLIOBLASTOMA ACTIVITY. (11th November 2019) Authors: Pruss, Maximilian; Dwucet, Annika; Hlavac, Michal; Kast, Richard; Westhoff, Mike-Andrew; Wirtz, Rainer; Halatsch, Marc-Eric; Siegelin, Markus; Karpel-Massler, Georg Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EXTH-48. INHIBITION OF SREBP-1 IS SYNTHETICALLY LETHAL WITH BCL-XL/BCL-2 INHIBITION IN GLIOBLASTOMA IN VITRO. (14th November 2022) Authors: Tosin, Davide; Schlotter, Dominik; Hajosch, Annika; Hlavac, Michal; Westhoff, Mike-Andrew; Siegelin, Markus; Wirtz, Christian Rainer; Karpel-Massler, Georg Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. EXTH-55. CONCOMITANT INHIBITION OF RAC1 AND Bcl-2/Bcl-xL INTERFERES WITH THE Mcl-1/Usp9X AXIS AND YIELDS SYNERGISTIC ANTI-GLIOMA ACTIVITY. (5th November 2018) Authors: Hlavac, Michal; Dwucet, Annika; Westhoff, Mike-Andrew; Kast, Richard Eric; Engelke, Jens; Siegelin, Markus; Wirtz, Christian Rainer; Halatsch, Marc-Eric; Karpel-Massler, Georg Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. EXTH-72. TTFIELDS ENHANCE THE ANTINEOPLASTIC ACTIVITY OF THE DRUG-REPURPOSING APPROACH CUSP9V3 IN GLIOBLASTOMA IN VITRO. (14th November 2022) Authors: Cao, Qiyu; Hajosch, Annika; Kast, Richard; Hlavac, Michal; Westhoff, Mike-Andrew; Siegelin, Markus; Wirtz, Christian Rainer; Halatsch, Marc-Eric; Karpel-Massler, Georg Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Immune phenotypes predict survival in patients with glioblastoma multiforme. Issue 1 (December 2016) Authors: Mostafa, Haouraa; Pala, Andrej; Högel, Josef; Hlavac, Michal; Dietrich, Elvira; Westhoff, M.; Nonnenmacher, Lisa; Burster, Timo; Georgieff, Michael; Wirtz, C.; Schneider, E. Journal: Journal of hematology & oncology Issue: Volume 9:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗